Searchable abstracts of presentations at key conferences in endocrinology

ea0086p7 | Adrenal and Cardiovascular | SFEBES2022

Adrenalectomy for unilateral primary aldosteronism improves quality of life: prospective analyses in the MATCH trial

Blackstone Brittany , Goodchild Emily , Tooze Oliver , Salsbury Jackie , Wu Xilin , Ronaldson Amy , Senanayake Russell , Bashari Waiel , Argentesi Giulia , O'Toole Samuel M. , Parvanta Laila , Sahdev Anju , Laycock Kate , Cruickshank Kennedy , Gurnell Mark , M. Drake William , Brown Morris J.

Background: After adrenalectomy (ADX) for primary aldosteronism (PA), approximately 30% of patients achieve clinical success (normalisation of home BP); many additional patients report feeling subjectively better. We used the non-randomised MATCH study1 to further assess quality of life (QoL) changes in participants.Objective: Assess QoL using the 36-item Short Form Health Survey (SF-36) after surgical treatment of unilateral PA and medical treatment of ...

ea0086p153 | Adrenal and Cardiovascular | SFEBES2022

Preliminary data from FABULAS: a Feasibility study of RadioFrequency endoscopic ABlation, with ULtrasound guidance, as a non-surgical, Adrenal Sparing treatment for aldosterone producing adenomas

Argentesi Giulia , Wu Xilin , Goodchild Emily , Laycock Kate , Ney Alexander , Senanayake Russell , MacFarlane James , Goodchild George , Wilson Patrick , Godfrey Ed , Gurnell Mark , Cheow Heok , P Pereira Stephen , M Drake William , J Brown Morris

Primary aldosteronism (PA) is the potentially curable cause of high-risk hypertension in 5-10% of unselected patients. Diagnosis and lateralisation of PA is challenging and complex. Outcomes post total adrenalectomy, the standard treatment for unilateral aldosterone producing adenomas (APAs), are variable. Between 30-60% are cured (1), but prediction of outcome is unreliable, and some patients are reluctant to have abdominal surgery to remove a whole adrenal gland. Endoscopic ...

ea0094p233 | Neuroendocrinology and Pituitary | SFEBES2023

Characterisation of the Impact of Joint Pain on Patients with Acromegaly

Hebden Sophie , Safdar Nawaz , Heague Megan , Lynch Julie , Mclaren David , Tresoldi Alberto , Lithgow Kirstie , Urwyler Sandrine , Akbar Shahzad , McLoughlin Katie , Kearney Tara , M Drake William , Sathyapalan Thozhukat , Orme Steve , E Higham Claire , Karavitaki Niki , Kyriakakis Nikolaos , Murray Robert

Acromegaly is caused by excessive growth hormone (GH) and insulin-like growth factor (IGF-1) secretion. Arthropathy is a leading cause of morbidity and impaired quality of life in acromegalic patients, often persisting despite therapeutic interventions and biochemical control. This cross-sectional study aimed to characterise the extent and impact of arthropathy in terms of pain and functional impairment. Validated questionnaires, including DASH (Disabilities of the Arm, Should...

ea0094oc3.5 | Neuroendocrinology and Pituitary | SFEBES2023

The effects of biochemical control and Arthropathy on Quality of Life in patients with Acromegaly: a cross-sectional study

Megan Heague , Nawaz Safdar , Sophie Hebden , Julie Lynch , David McLaren , Alberto Tresoldi , Kirstie Lithgow , Sandrine Urwyler , Shahzad Akbar , Katie McLoughlin , Tara Kearney , William M. Drake , Thozhukat Sathyapalan , Steve Orme , Claire E. Higham , Niki Karavitaki , Nikolaos Kyriakakis , Robert D. Murray

One of the most prevalent clinical manifestations of acromegaly is arthropathy which persists despite adequate symptom and biochemical control, and contributes to impaired quality of life. Patients with acromegaly have high psychiatry morbidity and increased prevalence of depression and poor psychological wellbeing. In a large cohort we aim to determine the effects of joint disease and disease control on quality of life in acromegaly. Eighty-five patients (45 women; median age...